Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-19269
Infante, R M; Ericsson, C D; Jiang, Z D; Ke, S; Steffen, R; Riopel, L; Sack, D A; DuPont, H L (2004). Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clinical Gastroenterology and Hepatology, 2(2):135-138.
|PDF - Registered users only|
BACKGROUND AND AIMS: We have recently shown that enteroaggregative Escherichia coli (EAEC) strains commonly cause travelers' diarrhea. The study was designed to determine whether U.S. travelers with EAEC diarrhea responded to rifaximin therapy. METHODS: In a multicenter placebo-controlled clinical trial of travelers' diarrhea without non-EAEC pathogens we evaluated 2 doses of rifaximin. EAEC was sought in stool samples in enrolled subjects by HEp-2 cell assay. Response to rifaximin (both groups combined) and placebo were evaluated in EAEC-positive and EAEC-negative patient groups. RESULTS: Compared with placebo, rifaximin shortened the postenrollment illness in travelers with EAEC diarrhea (median, 22 vs. 72 hours; P = 0.03). In subjects with EAEC-negative diarrhea, the median duration of post-treatment diarrhea was shorter with rifaximin (33 hours) than with placebo (52 hours), but this difference was not significantly different (P = 0.14). CONCLUSIONS: Improvement of EAEC-mediated diarrhea with antibiotic treatment supports the pathogenicity of this organism in travelers to developing countries. The study provides information on the value of the poorly absorbed drug rifaximin in therapy of travelers' diarrhea.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Institute of Social and Preventive Medicine|
|DDC:||610 Medicine & health|
|Deposited On:||17 Jun 2009 12:47|
|Last Modified:||27 Nov 2013 20:06|
|Citations:||Web of Science®. Times cited: 28|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page